Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.65 |
| ▸ | APP | P05067 | 6/20 | 0.63 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.61 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034559 | 1.00 | KDM4E (0.78) | KDM4ELMNAAKR1C3APPPTGER4 | |
| SCHEMBL5848040 | 0.91 | KDM4E (0.87) | KDM4ELMNAAKR1C3APPPTGER4 | |
| SCHEMBL27833553 | 0.91 | KDM4E (0.87) | KDM4ELMNAAKR1C3APPPTGER4 | |
| SCHEMBL5848038 | 0.91 | KDM4E (0.87) | KDM4ELMNAAKR1C3APPPTGER4 | |
| SCHEMBL18300366 | 0.90 | KDM4E (0.65) | KDM4ELMNAAKR1C3ALDH1A1HPGD | |
| SCHEMBL18300365 | 0.90 | KDM4E (0.65) | KDM4ELMNAAKR1C3ALDH1A1HPGD | |
| SCHEMBL1608804 | 0.89 | KDM4E (0.79) | KDM4ELMNAAKR1C3APPPTGER4 | |
| SCHEMBL1608802 | 0.89 | KDM4E (0.79) | KDM4ELMNAAKR1C3APPPTGER4 | |
| SCHEMBL1609269 | 0.89 | KDM4E (0.79) | KDM4ELMNAAKR1C3APPPTGER4 | |
| SCHEMBL1609268 | 0.89 | KDM4E (0.79) | KDM4ELMNAAKR1C3APPPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | KDM4E 509/4885LMNA 1816/4885AKR1C3 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.